EGFR-Targeted Perfluorohexane Nanodroplets for Molecular Ultrasound Imaging.
Sidhartha Jandhyala1, Austin Van Namen1, Catalina-Paula Spatarelu1
1Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.
Nanomaterials (Basel, Switzerland)
|July 9, 2022
Summary
Antibody-conjugated perfluorohexane nanodroplets (PFHnD-Ab) target cancer cells expressing epidermal growth factor receptor (EGFR). These novel ultrasound contrast agents show enhanced binding and imaging capabilities for molecular diagnostics.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Medical Imaging
Background:
- Perfluorocarbon nanodroplets offer advanced ultrasound contrast compared to microbubbles.
- Targeted contrast agents are crucial for molecular imaging in diagnostics.
Purpose of the Study:
- To develop antibody-conjugated perfluorohexane nanodroplets (PFHnD-Ab) for targeting epidermal growth factor receptor (EGFR)-overexpressing cells.
- To evaluate the efficacy of PFHnD-Ab as ultrasound contrast agents for molecular imaging.
Main Methods:
- Synthesis of perfluorohexane nanodroplets (PFHnD) with a phospholipid shell and DiD fluorescent dye.
- Antibody conjugation to PFHnD surface via hydrazide-aldehyde reaction.
- In vitro cellular binding assays and ultrasound imaging in tissue-mimicking phantoms.
Main Results:
- PFHnD-Ab demonstrated significantly higher cellular binding compared to non-targeted PFHnDs and controls.
- Ultrasound imaging revealed a significantly greater amplitude increase in cells with PFHnD-Abs.
- The developed nanodroplets showed specific targeting and enhanced contrast in ultrasound imaging.
Conclusions:
- Antibody-conjugated perfluorohexane nanodroplets are effective ultrasound contrast agents for targeting EGFR-expressing cells.
- This technology holds promise for advancing molecular imaging in cancer diagnostics.
- PFHnD-Ab represent a novel tool for enhancing ultrasound-based diagnostic capabilities.
